Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test

Pharmacological Reports

Volumn 64, Issue 6, 2012, Pages 1391-1399

  Rogóz, Zofia ^a   Kabziński, Marcin ^a   Sadaj, Witold ^a   Rachwalska, Paulina ^a   Ga̧dek Michalska, Anna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Fluoxetine; Forced swim test; Mirtazapine; Plasma corticosterone level; Rats; Risperidone

Indexed keywords

CORTICOSTERONE; FLUOXETINE; MIRTAZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PLIVA; RISPERIDONE; TOCRIS; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLIMBING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; EVOKED RESPONSE; EXPLORATORY BEHAVIOR; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MONOTHERAPY; NONHUMAN; RAT; STRESS;

EID: 84873709663     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70936-2     Document Type: Article

References (37)

1. Amsterdam JD, Hornig-Rohan M: Treatment algorithms in treatment-resistant depression. Psychiatry Clin North Am, 1996, 19, 371-386. (Pubitemid 26184108)
2. 2C receptor mediated oxytocin, prolactin and ACTH/corticosterone responses. Behav Brain Res, 1996, 73, 277-280.
3. Brady LS, Whitfield HJ, Fox RJ, Gold PW, Herkenham M: Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest, 1991, 87, 831-837.
4. Burda K, Czubak A, Kuoe K, Nowakowska E, Ratajczak P, Zin J: Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep, 2011, 63, 898-907.
5. Connor TJ, Kelliher P, Shen Y, Harkin A, Kelly JP, Leonard BE: Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol Biochem Behav, 2000, 65, 591-597. (Pubitemid 30182501)
6. Connor TJ, Kelly JP, Leonard BE: Forced swim test - induced endocrine and immune changes in the rat: effect of subacute desipramine treatment. Pharmacol Biochem Behav, 1998, 59, 171-177. (Pubitemid 28053695)
7. Croom KF, Perry CM, Plosker GL: Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs, 2009, 23, 427-452.
8. Detke MJ, Rickels M, Lucki I: Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl), 1995, 121, 66-72.
9. Dhir A, Kulkarni SK: Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors. Neurosci Lett, 2008, 445, 83-88.
10. Duncan GE, Knapp DJ, Carson SW, Breese GR: Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone. J Pharmacol Exp Ther, 1998, 285, 579-589.
11. Feldman S, Newman ME, Gur E, Weidenfeld J: Role of serotonin in the amygdale in hypothalamo-pituitaryadrenocortical receptors. Neuroreport, 1998, 9, 2007-2009. (Pubitemid 28300556)
12. Ga̧dek-Michalska A, Tadeusz J, Rachwalska P, Spyrka J, Bugajski J: Effect of prior stress on interleukin-1β and HPA axis responses to acute stress. Pharmacol Rep, 2011, 63, 1393-1403.
13. Heuser IJE, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F: Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry, 1996, 153, 93-99. (Pubitemid 26026163)
14. Hirose S, Ashby CR: An open pilot study combining risperidone and selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry, 2002, 63, 733-736.
15. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 2000, 23, 477-501.
16. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary- adrenalcortical regulation. Endocrine Rev, 1996, 17, 187-205.
17. Karandrea D, Kittas C, Kitraki E: Forced swimming differential affects male and female brain corticosteroid receptors. Neuroendocrinology, 2002, 75, 217-226. (Pubitemid 34455095)
18. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB: A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatry Res, 2009, 43, 205-214.
19. Korstein SG, Schneider RK: Clinical festures of treatment-resistant depression. J Clin Psychiatry, 2001, 62, Suppl 16, 18-25.
20. Kumar R, Palit G, Dhawan BN: Comparative behavioral effects of typical and atypical antipsychotic drugs in rhesus monkey. Eur J Pharmacol, 2003, 462, 133-138. (Pubitemid 36183744)
21. Murphy BEP: Antiglucocorticoid therapies in major depression: a review. Psychoendocrinology, 1997, 22, Suppl 1, S125-S132.
22. Nierenberg AA, Amsterdam JD: Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry, 1990, 51, 39-47. (Pubitemid 20212863)
23. Nowakowska E, Kuoe K, Polański A, Burda K, Nowakowska A, Sadowski C: Concomitant use of carbamazapine and olanzapine and the effect on some behavioral functions in rats. Pharmacol Rep, 2011, 63, 372-380.
24. O'Connor M, Silver H: Additing risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol, 1998, 18, 89-91. (Pubitemid 28045644)
25. Ostroff RB, Nelson J: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry, 1999, 60, 256-259. (Pubitemid 29193925)
26. Pariante CM: Depression, stress and the adrenal axis. J Neuroendocrinol, 2003, 15, 811-812.
27. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry, 2001, 49, 391-404. (Pubitemid 32234301)
28. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I et al.: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology, 2006, 31, 2505-2513. (Pubitemid 44607069)
29. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci, 2000, 68, 29-39.
30. Rogóż Z: Effects of co-treatment with mirtazapine and low doses of risperidone on the immobility time in the forced swimming test in mice. Pharmacol Rep, 2010, 62, 1191-1196.
31. Rogó̇ Z, Kabziński M: Enhancement of the antiimmobility action of antidepressants by risperidone in the forced swimming test in mice. Pharmacol Rep, 2011, 63, 1533-1538.
32. Sanches C, Hyttel J: Comparison of the effect of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol, 1999, 19, 467-489.
33. Satoh T, Yamada K, Tsuboi M: Effect of imipramine on serum corticosterone levels in forced swimming rats. Res Comm Psychol Behav, 1985, 10, 235-238. (Pubitemid 16231675)
34. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl), 1996, 124, 57-73. (Pubitemid 26112775)
35. Shelton RC: Treatment options for refractory depression. J Clin Psychiatry, 1999, 60, Suppl 4, 57-61.
36. Shelton RC, Papakostas GI: Augmentation of antidepressants with atypical antypsychotics for treatment-resistant major depressive disorder. Acta Psychiatry Scand, 2008, 117, 253-259. (Pubitemid 351350599)
37. Weber CC, Eckert GP, Muller WE: Effect of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology, 2006, 31, 2443-2448. (Pubitemid 44607062)